All News

Salvage high-intensity focused ultrasound (HIFU) appears to be an effective treatment option for locally recurrent prostate cancer after primary external beam radiation therapy (EBRT), data from analyses of 6-year oncologic outcomes show.

The treatment benefit of intradetrusor onabotulinumtoxinA (Botox) for urinary incontinence due to neurogenic detrusor overactivity may decline after patients have received multiple repeat injections, findings from a study by Taiwanese urologists suggest.

With the presidential election looming, we thought it would be appropriate to look at the visions for health care reform put forth by the two presidential candidates, with an eye toward what a urology practice should do today to prepare for the future.

Adoption of robotic surgery for treatment of kidney cancer has led to a modest increase in the annual volume of partial nephrectomies but a substantial cost savings for care of chronic kidney disease, an economic analysis of a 6-year period suggests.

There is never a bad time to revisit the beneficiary designations you have made over the years.

While most of the urologists we interviewed use non-physician providers, they don't believe these practitioners are adequately trained to do cystoscopy.

Patients with early-stage kidney cancer fared much better with partial rather than radical nephrectomy if they were candidates for either procedure, say researchers from the University of Michigan, Ann Arbor.

Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an analysis of 1,059 patients who participated in six clinical trials of sunitinib as first- or second-line therapy of metastatic renal cell carcinoma.

It's hard to argue with the statement that no ischemia is probably better than some ischemia, but at what cost?

An underfilled schedule and increasing no-show rate are just two of the pitfalls to avoid.

Howard Goldman, MD, discusses the possible effects of FDA reclassification of transvaginal mesh used for prolapse as well as the importance of adequate surgical training and patient selection.

An implantable neurostimulator (InterStim, Medtronic, Minneapolis) improves voiding outcomes in patients with voiding dysfunction that is refractory to other therapies, a retrospective long-term follow-up of patients at a single center showed.

The recently published meaningful use Stage 2 final rule will directly affect urology practices.

Urologists share some simple methods and techniques that make their job easier.

Osteoporosis, pelvic organ prolapse, and incontinence are common in postmenopausal women and may share a common pathway, a recent study suggests.

Results of a recent study support the use of barbed polyglyconate sutures to facilitate vesicourethral anastomosis (VUA) during robot-assisted radical prostatectomy.

A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.

Attorney Dawn Collins, JD, reviews several malpractice cases involving urologists.

Rendering stone fragments paramagnetic by exposure to iron oxide-based microparticles shows promise as a novel approach for reducing the number of small retained fragments after ureteroscopic lithotripsy, say researchers who are developing the technology.

The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.

Functional recovery after partial nephrectomy correlated more closely with volume loss than with warm ischemia time, researchers from Cleveland Clinic's Glickman Urological and Kidney Institute recently reported.

A study from Duke University, Durham, NC suggests that folic acid may reduce the risk of prostate cancer recurrence following radical prostatectomy.

Controversies related to circumcision could lead to a rise in medical liability for urologists performing this procedure, writes the American Association of Clinical Urologists' Tim Lytle.

The difference in prostate cancer mortality among men with low-risk disease who choose active surveillance versus those who choose immediate treatment with radical prostatectomy is likely to be very modest—possibly as little as 2 to 3 months—a new research model has estimated.

Individuals with at least one symptomatic kidney stone episode have significantly heightened risks of end-stage renal disease (ESRD), chronic kidney disease, and sustained doubling of serum creatinine concentration, according to the results of a Canadian study.

New guidelines from the University of Michigan Health System, Ann Arbor, offer family physicians a step-by-step guide for the evaluation of urinary incontinence.

The FDA has approved the production and use of Choline C 11 Injection, a positron emission tomography agent used to help detect recurrent prostate cancer.